- Home
- DOUG vs LCTX Comparison
DOUG vs LCTX Comparison
Compare DOUG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- LCTX
- Stock Information
- Founded
- DOUG 1911
- LCTX 1990
- Country
- DOUG United States
- LCTX United States
- Employees
- DOUG N/A
- LCTX N/A
- Industry
- DOUG Building operators
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOUG Real Estate
- LCTX Health Care
- Exchange
- DOUG Nasdaq
- LCTX Nasdaq
- Market Cap
- DOUG 166.2M
- LCTX 165.6M
- IPO Year
- DOUG N/A
- LCTX N/A
- Fundamental
- Price
- DOUG $1.67
- LCTX $0.89
- Analyst Decision
- DOUG
- LCTX Strong Buy
- Analyst Count
- DOUG 0
- LCTX 3
- Target Price
- DOUG N/A
- LCTX $5.67
- AVG Volume (30 Days)
- DOUG 780.1K
- LCTX 432.3K
- Earning Date
- DOUG 11-05-2024
- LCTX 08-08-2024
- Dividend Yield
- DOUG N/A
- LCTX N/A
- EPS Growth
- DOUG N/A
- LCTX N/A
- EPS
- DOUG N/A
- LCTX N/A
- Revenue
- DOUG $951,674,000.00
- LCTX $6,186,000.00
- Revenue This Year
- DOUG $3.85
- LCTX N/A
- Revenue Next Year
- DOUG $17.40
- LCTX $119.00
- P/E Ratio
- DOUG N/A
- LCTX N/A
- Revenue Growth
- DOUG N/A
- LCTX N/A
- 52 Week Low
- DOUG $1.00
- LCTX $0.77
- 52 Week High
- DOUG $3.16
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- DOUG 44.48
- LCTX 47.03
- Support Level
- DOUG $1.42
- LCTX $0.83
- Resistance Level
- DOUG $1.91
- LCTX $0.90
- Average True Range (ATR)
- DOUG 0.17
- LCTX 0.05
- MACD
- DOUG -0.05
- LCTX 0.00
- Stochastic Oscillator
- DOUG 30.82
- LCTX 35.31
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.